The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
ORGANIZATION
PMP Drugs Should Be Excluded from Price Revisions: FPMAJ Committee Chief
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) is set to push for the exclusion of medicines qualified for the price maintenance premium (PMP) from drug price revisions as part of its requests towards the FY2026 drug pricing reform.…
To read the full story
Related Article
ORGANIZATION
- Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
January 21, 2026
- OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
January 20, 2026
- JETRO Picks 10 Overseas Startups for Regenerative Medicine Japan Entry Program
January 20, 2026
- Pharma FTC Clarifies “Simple Beverages” under New Food Rules
January 14, 2026
- EFPIA Japan Appoints Novartis’ Pullicino as Vice Chair
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…